CN108451965A - A kind of radix paeoniae rubra terpene glycoside composition and preparation method thereof with function of resisting myocardial ischemia - Google Patents
A kind of radix paeoniae rubra terpene glycoside composition and preparation method thereof with function of resisting myocardial ischemia Download PDFInfo
- Publication number
- CN108451965A CN108451965A CN201810415410.0A CN201810415410A CN108451965A CN 108451965 A CN108451965 A CN 108451965A CN 201810415410 A CN201810415410 A CN 201810415410A CN 108451965 A CN108451965 A CN 108451965A
- Authority
- CN
- China
- Prior art keywords
- radix paeoniae
- paeoniae rubra
- glycoside composition
- terpene glycoside
- myocardial ischemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Technical field of medicine of the present invention, and in particular to a kind of radix paeoniae rubra terpene glycoside composition with function of resisting myocardial ischemia, and preparation method and application are further disclosed.Radix paeoniae rubra terpene glycoside composition of the present invention with function of resisting myocardial ischemia, using Paeoniflorin, albiflorin, benzoylpaeoniflorin and oxypaeoniflorin as active ingredient, experiment shows that radix paeoniae rubra terpene glycoside composition of the present invention can inhibit Na2S2O4The H9C2 Myocytes Anoxias of induction damage, and can be widely applied to the medicine preparation of prevention myocardial ischemia disease.
Description
Technical field
A kind of technical field of medicine of the present invention, and in particular to radix paeoniae rubra terpene glycosides combination with function of resisting myocardial ischemia
Object, and preparation method and application are further disclosed.
Background technology
Myocardial ischemia (myocardial ischemia) refers to that the hemoperfusion of heart is reduced, and the oxygen supply of heart is caused to subtract
Few, energy metabolism of myocardial is abnormal, cannot support a kind of pathological state of normal heart action, and be easy to cause dysfunction,
Tissue damage, myocardial necrosis even result in sudden cardiac death.Since the required energy of cardiomotility is almost by there is oxo
Offer is provided, even if so when peace and quiet, myocardium blood oxygen uptake ratio also very high (about 70%), under normal circumstances, body
It can be adjusted by itself, promote blood supply and demand relative constant, ensure normal heart action.When certain reason causes myocardial blood to supply
Need to be unbalance, just constitute myocardial ischemia truly.With the improvement of people's living standards, myocardial ischemia is in China at present
Illness rate be in the trend that rises year by year, it has also become the common disease and frequently-occurring disease of the middle-aged and the old, some 20-30 Sui young men
There is the performance of myocardial ischemia.Therefore, the prevention of myocardial ischemia has become the important topic of China's hygiene medical treatment cause at this stage.
It is existing to resist myocardial ischemia mainly based on chemicals, but chemicals have relatively common nervous system and disappear
The symptoms such as headache, nausea, dizziness, fash, inability easily occur for the adverse reaction of change system.Chinese medicine is as safety medicine without side-effects
The representative of object, resisting myocardial ischemia, aspect plays an important role always.
It is ranunculaceae plant Chinese herbaceous peony Paeonia that radix paeoniae rubra, which is that clinically high frequency uses Chinese medicine, 2015 editions its sources of States Pharmacopoeia specifications,
The dry root of lactiflora PalL. or river radix paeoniae rubra Paeonia veitchii Lynch have clearing heat and cooling blood, dissipate stasis of blood analgesia
The effect of, it cures mainly thermal man's ying blood, febrile virulent maculae, hematemesis and epistaxis, red eye, swell pain, liver-depressed hypochondrium pain, closed dysmenorrhea, addiction lump in the abdomen abdominal pain, fall
Damage, carbuncle swells sore are flutterred, the prevention and treatment of cardiovascular and cerebrovascular disease is widely used in.But radix paeoniae rubra is used as medicine usually with decocting shape
Formula is unfavorable for the research and application of modern Chinese herbal medicine preparation since material base is not clear enough, is also unfavorable for effectively playing its anti-heart
The effect of myocardial ischemia.
Invention content
For this purpose, technical problem to be solved by the present invention lies in provide a kind of radix paeoniae rubra terpene glycosides with function of resisting myocardial ischemia
Composition, and preparation method and application are further disclosed.
In order to solve the above technical problems, a kind of radix paeoniae rubra terpene glycosides combination with function of resisting myocardial ischemia of the present invention
Object includes the ingredient of following mass content in terms of the total amount of the composition：Paeoniflorin 10.0-50.0wt%, albiflorin
5.0-30.0wt%, benzoylpaeoniflorin 1.0-30.0wt%, oxypaeoniflorin 1.0-30.0wt%.
The radix paeoniae rubra terpene glycoside composition with function of resisting myocardial ischemia, in terms of the total amount of the composition, including such as
The ingredient of lower mass content：Paeoniflorin 50.0wt%, albiflorin 25.0wt%, benzoylpaeoniflorin 15.0wt%, oxidation
Paeoniflorin 10.0wt%.
The invention also discloses a kind of methods preparing the radix paeoniae rubra terpene glycoside composition, including take a selected amount of Chinese herbaceous peony
The step of medicine glycosides, albiflorin, benzoylpaeoniflorin and oxypaeoniflorin are mixed.
The invention also discloses the radix paeoniae rubra terpene glycoside compositions to be used to prepare the drug with function of resisting myocardial ischemia
Purposes.
The invention also discloses by the radix paeoniae rubra terpene glycoside composition, selectivity adds customary adjuvant, according to common process
The manufactured clinically-acceptable drug with function of resisting myocardial ischemia.
The radix paeoniae rubra terpene glycoside composition accounts for the 5-100wt% of the drug total amount.
The drug includes oral preparations or external preparation.
The drug includes injection, tablet, capsule, granule, oral solution, pill, spray or emulsion.
The invention also discloses a kind of methods preparing the drug, including take a selected amount of Paeoniflorin, in Chinese herbaceous peony
The step of ester glycosides, benzoylpaeoniflorin and oxypaeoniflorin are mixed, and customary adjuvant is selectively added, according to common process
Manufactured clinically-acceptable drug.
Radix paeoniae rubra terpene glycoside composition of the present invention with function of resisting myocardial ischemia, with Paeoniflorin, albiflorin, benzene
Formyl Paeoniflorin and oxypaeoniflorin are active ingredient, and experiment shows radix paeoniae rubra terpene glycoside composition of the present invention to Na2S2O4It lures
Leading H9C2 cardiac muscle cell has certain protective effect.After H9C2 cell hypoxias, obstacle, Na occur for energetic supersession+-K+-
ATP enzyme, Mg2+ATP enzyme etc. can be by ATP catalyzing hydrolysis, while releasing energy, and environment pH is reduced, and leads to SOD, CAT, GSH-Px
Isoreactivity reduces；The oxygen radical of accumulation is reacted with membrane lipid generates peroxide MDA, further damaging cells to rupture, CK,
The myocardium enzymes such as LDH, AST are revealed.And radix paeoniae rubra terpene glycoside composition of the present invention, on the one hand it can swash in energy imbalance of supply and demand
ATP enzyme living releases energy, on the other hand scavenging activated oxygen and peroxide under oxidative stress status, to remain intracellular
Stable state reduces Apoptosis.This distinctive protective effect, it will make radix paeoniae rubra terpene glycoside composition in the prevention of myocardial ischemia disease
It is middle to be widely applied.
Radix paeoniae rubra terpene glycoside composition of the present invention with function of resisting myocardial ischemia is ground using Apoptosis theory as background
Study carefully and illustrate the mechanism of action of the radix paeoniae rubra terpene glycoside composition, the research and development for myocardial ischemia protective agents provide target spot and plan
Slightly, new drug candidate is provided for myocardial ischemia disease, can be used for the exploitation of modern Chinese herbal medicine preparation.
Description of the drawings
In order to make the content of the present invention more clearly understood, it below according to specific embodiments of the present invention and combines
Attached drawing, the present invention is described in further detail, wherein
Fig. 1 is influence of the radix paeoniae rubra terpene glycosides concentration to H9C2 cell survival rates；
Fig. 2 is radix paeoniae rubra terpene glycosides to Na2S2O4Induce the influence of H9C2 cell CK, LDH, SOD and MDA vigor；
Fig. 3 is radix paeoniae rubra terpene glycosides to Na2S2O4Induce the influence of H9C2 apoptotic indexes；
Fig. 4 is radix paeoniae rubra terpene glycosides to Na2S2O4Induce the influence of H9C2 cell ultrastructures；
Fig. 5 is radix paeoniae rubra terpene glycosides to Na2S2O4Induce the influence of H9C2 cell death related proteins expression；
Fig. 6 is radix paeoniae rubra terpene glycosides to Na2S2O4Induce the influence of H9C2 cell mitochondrials mRNA expression.
Specific implementation mode
1 injection of embodiment
Radix paeoniae rubra terpene glycoside composition described in the present embodiment includes：Paeoniflorin 50.0wt%, albiflorin 25.0wt%, benzene first
Acyl Paeoniflorin 15.0wt%, oxypaeoniflorin 10.0wt%.
A selected amount of above-mentioned radix paeoniae rubra terpene glycoside composition is dissolved with water for injection, is slowly added to sodium bicarbonate and continuous by several times
Stirring is added sodium pyrosulfite dissolving, adds to the full amount of water for injection when liquid level bubble-free generates；Then measured with pH acidity
Determine liquid pH value and should be 5.5-8.0, if not in this range, can be adjusted with niter cake；Take obtained liquid with No. 3 incipient fusion glass
Pan is filtered to clear and bright, embedding ampoule, 100 DEG C, sterilize within 30 minutes to get.
2 capsule of embodiment
Radix paeoniae rubra terpene glycoside composition described in the present embodiment includes：Paeoniflorin 50.0wt%, albiflorin 5.0wt%, benzene first
Acyl Paeoniflorin 30.0wt%, oxypaeoniflorin 15.0wt%.
Appropriate amount of starch is added in a selected amount of above-mentioned radix paeoniae rubra terpene glycoside composition to mix, particle is made, it is dry, it is uniformly mixed,
Capsule is packed into get capsule.
3 capsule of embodiment
Radix paeoniae rubra terpene glycoside composition described in the present embodiment includes：Paeoniflorin 50.0wt%, albiflorin 30.0wt%, benzene first
Acyl Paeoniflorin 19.0wt%, oxypaeoniflorin 1.0wt%.
Appropriate dextrin is added in a selected amount of above-mentioned radix paeoniae rubra terpene glycoside composition to mix, particle is made, it is dry, it is uniformly mixed,
Capsule is packed into get capsule.
4 capsule of embodiment
Radix paeoniae rubra terpene glycoside composition described in the present embodiment includes：Paeoniflorin 50.0wt%, albiflorin 30.0wt%, benzene first
Acyl Paeoniflorin 1.0wt%, oxypaeoniflorin 19.0wt%.
Appropriate lactose is added in a selected amount of above-mentioned radix paeoniae rubra terpene glycoside composition and MCC is mixed, particle is made, dry, mixing
Uniformly, capsule is packed into get capsule.
5 tablet of embodiment
Radix paeoniae rubra terpene glycoside composition described in the present embodiment includes：Paeoniflorin 10.0wt%, albiflorin 30.0wt%, benzene first
Acyl Paeoniflorin 30.0wt%, oxypaeoniflorin 30.0wt%.
A selected amount of above-mentioned radix paeoniae rubra terpene glycoside composition is mixed with starch, particle is made, it is dry, by particle and talcum powder,
Magnesium stearate is uniformly mixed, and tabletting is to get tablet.
6 tablet of embodiment
Radix paeoniae rubra terpene glycoside composition described in the present embodiment includes：Paeoniflorin 47.0wt%, albiflorin 15.0wt%, benzene first
Acyl Paeoniflorin 18.0wt%, oxypaeoniflorin 20.0wt%.
A selected amount of above-mentioned radix paeoniae rubra terpene glycoside composition is mixed with dextrin, particle is made, it is dry, by particle and talcum powder,
Magnesium stearate is uniformly mixed, and tabletting is to get tablet.
7 tablet of embodiment
Radix paeoniae rubra terpene glycoside composition described in the present embodiment includes：Paeoniflorin 20.0wt%, albiflorin 30.0wt%, benzene first
Acyl Paeoniflorin 25.0wt%, oxypaeoniflorin 25.0wt%.
A selected amount of above-mentioned radix paeoniae rubra terpene glycoside composition is mixed with lactose, particle is made, it is dry, by particle and talcum powder,
Magnesium stearate is uniformly mixed, and tabletting is to get tablet.
Experimental example
1, MTT detects H9C2 cell viabilities
H9C2 cells in good condition are taken, are blown and beaten uniformly with the incomplete high glucose mediums of DEME, it is 1 × 10 to prepare density6
A/mL cell suspensions, then be inoculated in 96 orifice plates with 100 μ L of every hole, in 37 DEG C, 5%CO2In the environment of cultivate for 24 hours, absorb
Blank cultures or the implementation of a concentration of 1600,800,400,200,100,50,25,12.5,6.25 μ g/mL is added in culture medium
100 μ L of terpene glycoside composition are made in example 1 and discard culture medium after continuing culture for 24 hours, 100 μ of MTT solution of 0.5mg/mL is added per hole
L continues to cultivate 4h, discards Incubating Solution, add 100 μ L DMSO, after 37 DEG C of constant-temperature tables vibrate 10min, utilizes microplate reader
Each hole absorbance (OD) is measured at 570nm, calculates each group cell survival rate (%), selects the most highly concentrated of survival rate (%) >=95%
Degree is the administration concentration of the radix paeoniae rubra terpene glycoside composition.
The radix paeoniae rubra terpene glycoside composition administration concentration of the result is shown in Figure 1, H9C2 cells is 200,100,50,25,12.5,6.25 μ
When g/mL, H9C2 cell survival rates are all higher than 95%, and when administration concentration is 400 μ g/mL, H9C2 cell survival rates are less than
95%, and increase with concentration, cell survival rate continuously decreases, therefore selects 200 μ g/mL radix paeoniae rubra terpene glycosides culture solutions, is subsequently ground
Study carefully.
2, the measurement of kinases and peroxidase
Absorbance value is measured using microplate reader or ultraviolet specrophotometer, it is specific as follows：Visible light method is divided at 660nm
It Ce Ding not creatine kinase (CK) vigor；WST-1 methods measure superoxide dismutase (SOD) vigor at 450nm；Micro enzyme mark
Method measures lactic dehydrogenase (LDH) vigor at 450nm；TBA methods measure malonaldehyde (MDA) content at 532nm.
Radix paeoniae rubra terpene glycoside composition is to Na2S2O4Induce the myocardium enzyme of H9C2 cells that there is adjustment effect, as a result as shown in Figure 2.
By Na2S2O4After stimulation, CK, LDH, MDA vigor have pole to be obviously improved (p<0.01), SOD vigor significantly reduces (p<
0.01)；Radix paeoniae rubra terpene glycoside composition has extremely significant restitution (p to CK, LDH, SOD and MDA<0.01).
3, flow cytometer measures the apoptotic index of H9C2 cells
The good H9C2 cells of collection status add the incomplete high glucose mediums of DEME (containing 10%FBS), and it is 1 to prepare density
×106A/mL cell suspending liquids, then be inoculated in 6 orifice plates with the holes 2.0mL/, and it is divided into blank, model and the combination of radix paeoniae rubra terpene glycosides
3 groups of object etc., every group sets 3 multiple holes, 37 DEG C, 5%CO2After culture for 24 hours, culture medium is discarded, 2.0mL skies are respectively added in blank, model group
White culture medium, each administration group are separately added into radix paeoniae rubra terpene glycosides (embodiment 1 is made), the representative ingredient a+b+c culture solutions of 2.0mL,
Move into incubator culture for 24 hours；Culture solution in hole is abandoned in suction, and 2.0mL blank cultures are added in blank group, and 2.0mL is added in remaining each group
4mM Na2S2O4Afterwards, after continuing culture for 24 hours, after pancreatin digestion, PBS are washed twice, H9C2 cells is collected, are buffered using combining
Liquid is blown and beaten at 1 × 106A/mL cell suspending liquids draw 100 μ L, and 5 μ L Annexin V-FITC and 10 μ L propidium iodides are added,
After being protected from light room temperature reaction 15min, 150 μ L combination buffers are added dropwise, and (excitation wave is detected using flow cytometer in 1h
Long 488nm, launch wavelength 530nm), it is counted using BD FACS softwares, calculates the apoptotic index of each group H9C2 cells.
As a result as shown in Figure 3, Na2S2O4Induction can significantly induce H9C2 Apoptosis, apoptosis rate from normal cell 4.79
± 0.37% is increased to 38.92 ± 3.25% (* p<0.01) H9C2 cells damage can be substantially reduced by, giving 200 μ g/mL radix paeoniae rubra terpene glycosides
Wound, apoptosis rate are down to 18.17 ± 1.13% respectively, illustrate the cell that radix paeoniae rubra terpene glycoside composition can obviously inhibit anoxia-induced apoptosis to guide
Apoptosis.
4, the ultra microstructure of transmission electron microscope analysis H9C2 cells
Cell is collected, is placed in 3% glutaraldehyde solution that fixed, PBS washings, 1% to starve sour fixation, graded ethanol acetone de-
It is observed after water, embedding, polymerization, ultra-thin section, lead dye.
As a result as shown in Figure 4, normally group cardiac muscle cell's mitochondria and myofilament structure are normal, and anaerobic environment can cause into the cell
Respiration rate slows down, and nucleus becomes larger, and Mitochondrial Shape also changes, such as swelling, disintegration, ridge or reduction or disappearance.If pre-
200 μ g/mL radix paeoniae rubra terpene glycosides are first given, apparent mitochondrial swelling and disintegration is not found, illustrates that radix paeoniae rubra terpene glycoside composition can be apparent
Mitigate Na2S2O4The H9C2 cell mitochondrials of induction damage.
5, detected by Western blot detection H9C2 apoptosis proteins expression
Cell is collected, the PBS rinses of precooling twice, cell protein, 13000rpm are extracted on ice bath with RIPA lysates
10min is centrifuged, supernatant is collected；Using BCA protein determination kits, Coomassie brilliant blue measures albumen concentration；Take 50 μ g albumen
Measure loading SDS-PAG gels, go to pvdf membrane after electrophoresis, after 5% skimmed milk power closes 2h, then respectively with cleaved
Caspase-3 (CST, 9664), Bax (Abcam, ab182734), Bcl-2 (Proteintech, 12789-1-AP) antibody (1：
500 dilutions), 4 DEG C of overnight incubations.β-actin (Abcam, ab8227) are used as internal standard, TBST to rinse 3 times, add secondary antibody (horseradish mistake
Oxide enzymic-labelled antibody), it is incubated 2h at room temperature, TBST is washed 3 times, adds ECL luminescence reagents to be incubated 1min, film exists in darkroom
It is exposed on photographic film and washes picture, image analysis software Image Pro Plus (IPP 6.0, Media with printing paper development
Cybernetics, USA) gray scale scanning is carried out, the absorbance ratio of Capase-3, Bax, Bcl-2 and β-actin are calculated, is represented
The relative expression quantity of its each albumen.
Western blot results are shown in described in Fig. 5, after effect for 24 hours, compared with blank group, in model group in H9C2 cells
The significant difference of Bax, Bcl-2 and Caspase-3 protein expression, Bax and Caspase-3 protein expression levels significantly increase (p
<0.01), Bcl-2 protein expression levels significant decrease (p<0.01)；Radix paeoniae rubra terpene glycoside composition (200 μ g/mL) can significantly drop
The pro apoptotic proteins such as low Bax and Caspase-3 express (p<0.01), increase anti-apoptotic proteins Bcl-2 protein expression levels (p<
0.01) no difference of science of statistics (p, and between two groups>0.05).
6, Real-Time PCR detect the relevant mRNA contents of H9C2 cell Mitochondrias
By extracting and purifying operating method, by the H9C2 cell extraction total serum IgEs of collection.Pass through ultraviolet light spectrophotometric determination
Absorbance value calculates the purity and concentration of total serum IgE.Each group RNA (2 μ g), 2 μ L OligodT (18) (50 μM) are taken, DEPC water is added
The RNase inhibitor of 0.5 μ L, 4.0 5 × Reaction of μ L are sequentially added to 12.5 μ L, 65 DEG C of heat preservations 5min, ice bath 5min
Buffer, 2.0 μ L 10mMdNTPS and 1.0 μ L M-MuLV, mixing, 2000rpm centrifuge 20s, 42 DEG C of heat preservation 1h, 70 DEG C of heat preservations
10min, on ice 5min, after synthesizing the first chains of cDNA, using Real-Time PCR detections Ndufa4, Ndufa8, Cox7a2,
TFAM。
As a result as shown in Figure 6, compared with blank group, Na2S2O4Model group H9C2 cells Ndufa4, Ndufa8, Cox7a2,
TFAM mRNA expressions have pole to be decreased obviously (p<0.01), show Na2S2O4The micro-environmental hypoxia of induction is to H9C2 cell lines
Plastochondria has apparent damaging action.Illustrate radix paeoniae rubra terpene glycoside composition of the present invention can significantly improve Ndufa4, Ndufa8,
Cox7a2, TFAM, and all no difference of science of statistics (p between two groups of each index>0.05).
Obviously, the above embodiments are merely examples for clarifying the description, and does not limit the embodiments.It is right
For those of ordinary skill in the art, can also make on the basis of the above description it is other it is various forms of variation or
It changes.There is no necessity and possibility to exhaust all the enbodiments.And it is extended from this it is obvious variation or
It changes still within the protection scope of the invention.
Claims (9)
1. a kind of radix paeoniae rubra terpene glycoside composition with function of resisting myocardial ischemia, which is characterized in that in terms of the total amount of the composition,
Include the ingredient of following mass content：Paeoniflorin 10.0-50.0wt%, albiflorin 5.0-30.0wt%, benzoyl Chinese herbaceous peony
Glycosides 1.0-30.0wt%, oxypaeoniflorin 1.0-30.0wt%.
2. the radix paeoniae rubra terpene glycoside composition according to claim 1 with function of resisting myocardial ischemia, which is characterized in that with described
The total amount meter of composition, includes the ingredient of following mass content：Paeoniflorin 50.0wt%, albiflorin 25.0wt%, benzene first
Acyl Paeoniflorin 15.0wt%, oxypaeoniflorin 10.0wt%.
3. a kind of method preparing radix paeoniae rubra terpene glycoside composition as claimed in claim 1 or 2, which is characterized in that including taking selected amount
The Paeoniflorin, albiflorin, benzoylpaeoniflorin and oxypaeoniflorin the step of being mixed.
4. radix paeoniae rubra terpene glycoside composition as claimed in claim 1 or 2 is used to prepare the purposes of the drug with function of resisting myocardial ischemia.
5. by radix paeoniae rubra terpene glycoside composition as claimed in claim 1 or 2, selectivity adds customary adjuvant, is made according to common process
The clinically-acceptable drug with function of resisting myocardial ischemia.
6. drug according to claim 4, which is characterized in that the radix paeoniae rubra terpene glycoside composition accounts for the 5- of the drug total amount
100wt%.
7. according to claim 4-6 any one of them drugs, which is characterized in that the drug includes oral preparations or external application system
Agent.
8. drug according to claim 7, which is characterized in that including injection, tablet, capsule, granule, take orally
Liquid, pill, spray or emulsion.
9. a kind of method preparing any one of claim 5-8 drugs, which is characterized in that including taking a selected amount of Chinese herbaceous peony
The step of medicine glycosides, albiflorin, benzoylpaeoniflorin and oxypaeoniflorin are mixed, and customary adjuvant is selectively added,
According to clinically-acceptable drug made of common process.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810415410.0A CN108451965A (en) | 2018-05-03 | 2018-05-03 | A kind of radix paeoniae rubra terpene glycoside composition and preparation method thereof with function of resisting myocardial ischemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810415410.0A CN108451965A (en) | 2018-05-03 | 2018-05-03 | A kind of radix paeoniae rubra terpene glycoside composition and preparation method thereof with function of resisting myocardial ischemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108451965A true CN108451965A (en) | 2018-08-28 |
Family
ID=63214507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810415410.0A Pending CN108451965A (en) | 2018-05-03 | 2018-05-03 | A kind of radix paeoniae rubra terpene glycoside composition and preparation method thereof with function of resisting myocardial ischemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108451965A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111759891A (en) * | 2020-08-19 | 2020-10-13 | 黑龙江中医药大学 | Pharmaceutical composition for treating myocardial ischemia and application thereof |
| CN114796142A (en) * | 2022-04-08 | 2022-07-29 | 黄山学院 | Naproxen gastric floating tablet and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101077364A (en) * | 2006-05-22 | 2007-11-28 | 周亚伟 | Traditional Chinese medicine composition for treating cardio cerebrovasculer disease and its preparations and preparation method |
| CN101204430A (en) * | 2006-12-21 | 2008-06-25 | 周亚伟 | Extractive of total peony ladves glucoside, preparation method and uses thereof |
| CN105796581A (en) * | 2016-03-13 | 2016-07-27 | 长春中医药大学 | Application of paeoniflorin to preparation of medicine for regulating and controlling cholinergic anti-inflammatory pathway |
-
2018
- 2018-05-03 CN CN201810415410.0A patent/CN108451965A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101077364A (en) * | 2006-05-22 | 2007-11-28 | 周亚伟 | Traditional Chinese medicine composition for treating cardio cerebrovasculer disease and its preparations and preparation method |
| CN101204430A (en) * | 2006-12-21 | 2008-06-25 | 周亚伟 | Extractive of total peony ladves glucoside, preparation method and uses thereof |
| CN105796581A (en) * | 2016-03-13 | 2016-07-27 | 长春中医药大学 | Application of paeoniflorin to preparation of medicine for regulating and controlling cholinergic anti-inflammatory pathway |
Non-Patent Citations (6)
| Title |
|---|
| 丁兰婷: "赤苷脉通注射液对实验性心肌缺血的保护作用及其机制研究", 《中国优秀硕士论文全文数据库 医药卫生科技辑》 * |
| 丁兰婷等: "赤苷脉通注射液对麻醉犬急性心肌缺血的保护作用", 《安徽医药》 * |
| 封亮等: "赤芍萜苷组分抗缺血缺氧损伤的代表性成分的发现与验证", 《药学学报》 * |
| 杨明: "《中药药剂学》", 31 July 2016, 中国中医药出版社 * |
| 柯仲成等: "基于代表性成分辨识的中药组分整体生物药剂学性质表征探讨", 《中国中药杂志》 * |
| 胡杰等: "UPLC-MS同时测定赤芍中五个指标成分的含量", 《天然产物研究与开发》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111759891A (en) * | 2020-08-19 | 2020-10-13 | 黑龙江中医药大学 | Pharmaceutical composition for treating myocardial ischemia and application thereof |
| CN114796142A (en) * | 2022-04-08 | 2022-07-29 | 黄山学院 | Naproxen gastric floating tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Astaxanthin from Haematococcus pluvialis ameliorates the chemotherapeutic drug (doxorubicin) induced liver injury through the Keap1/Nrf2/HO-1 pathway in mice | |
| Li et al. | Exogenous hydrogen sulfide ameliorates diabetic myocardial fibrosis by inhibiting cell aging through SIRT6/AMPK autophagy | |
| Yu et al. | Resveratrol activates PI3K/AKT to reduce myocardial cell apoptosis and mitochondrial oxidative damage caused by myocardial ischemia/reperfusion injury | |
| Worth Jr et al. | New features of inclusion disease of infancy | |
| CN108451965A (en) | A kind of radix paeoniae rubra terpene glycoside composition and preparation method thereof with function of resisting myocardial ischemia | |
| Xiang et al. | Protective effect and mechanism of chitooligosaccharides on acetaminophen-induced liver injury | |
| CN106950371B (en) | At least one of PD-L1, CDK5 and CTLA4 are preparing the purposes in tumor diagnosis kit | |
| Alsawalha et al. | Anti-diabetic activities of Dactylorhiza hatagirea leaf extract in 3T3-L1 cell line model | |
| CN105193795B (en) | Application of two kinds of halophenol compounds in terms of angiogenesispromoting effect | |
| Fantham | The life-history of Trypanosoma gambiense and Trypanosoma rhodesiense as seen in rats and guinea-pigs | |
| Liang et al. | Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis | |
| CN116407531A (en) | Application of anhydroicaritin in preparation of drugs for inhibiting macrophage iron death to treat atherosclerosis | |
| CN103142774B (en) | Application of total saponin extract of lobedfruit schizocapsarhizome in treatment of liver cancer and nasopharyngeal carcinoma | |
| CN105878233A (en) | Application of artemisinin derivative in preparing medicine for treating hepatic fibrosis | |
| CN113599412A (en) | Application of radix codonopsis and radix astragali composition in preparation of medicine for preventing and treating symptoms related to advanced tumor | |
| CN104434940A (en) | Application of panax japonicus IV a in prevention and treatment of cardiovascular disease and complication of cardiovascular disease | |
| CN101658576B (en) | Purpose of pummelo peel general flavone in preparing medicament for treating alcoholic liver injury | |
| CN107468681B (en) | The drug and pharmaceutical composition of prevention or treatment prediabetes | |
| WO2020211511A1 (en) | Use of ginkgolide composition in preparation of drug for acute coronary syndrome | |
| CN114957277B (en) | Compound for preventing and treating cerebral apoplexy and neurodegenerative diseases, and preparation method and application thereof | |
| Li et al. | Anthrahydroquinone-2, 6-disulfonate alleviates paraquat-induced kidney injury via the apelin-APJ pathway in rats | |
| Xiong et al. | Rhein Activates Janus Protein Tyrosine Kinase2/Signal Transducer and Transcription Activation Factor3 Reduces Mitochondrial Oxidative Damage Caused by Myocardial Ischemia/Reperfusion Injury | |
| CN114146087B (en) | Application of rhynchophylline in medicine for treating thrombocytopenia | |
| CN115025072B (en) | Application of squalene in preparation of medicines for treating renal ischemia reperfusion injury | |
| CN107260752A (en) | A kind of pharmaceutical composition of collaboration anti-pancreatic cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180828 |
|
| RJ01 | Rejection of invention patent application after publication |